NovaBay Pharmaceuticals (NBY) Stock Continues Skyward

NovaBay Pharmaceuticals NBY Stock News

After gaining nearly 6 times its value yesterday, NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN: NBY) is continuing its run for the top in the market this morning. The stock is up more than 28% in the pre-market trading as excitement continues surrounding the company’s product launch on (NASDAQ: AMZN). Here’s what you need to know:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Why NBY Stock Is Rocketing

The tremendous gains that we’ve seen in NovaBay Pharmaceuticals over the past couple of trading session are ultimately the result of the company’s announcement that it has launched a new product on

The company said in a press release yesterday morning that its Avenova Direct eyelid and eyelash spray has launched on without a prescription required. The product comes in a 20ml size with an affordable price of just $29.99, as can be seen on the Amazon product page.

The eyelid and eyelash spray was developed as a tool to remove bacteria and debris around the eyelid that is known to lead to ocular bacterial infections. This is a key indication as ocular bacterial infections are blamed for approximately 85% of dry eye cases.

Why This Is Leading To Such Investor Excitement

Ultimately, there are a couple of reasons that investors are so excited about the news:

  • Offers A Huge Audience is the world’s largest eCommerce platform. As such, the fact that NBY launched its product on the website will likely put the product in front of a large audience, helping to ensure a strong product launch.
  • The Dry Eye Market Is Massive – It’s also worth mentioning that the dry eye market is a massive one. In fact, by the year 2025, it is expected that the market will grow to be worth more than $7.7 billion. Even after the tremendous gains that we’ve seen from the stock over the past couple of trading sessions, it still trades with a market cap of just over $50 million. Even if the company were only able to capture 1% of the dry eye market, it would be capturing sales of $77 million per year.

At the end of the day, with the large audience that provides, and the tremendous opportunity offered up by the sheer size of the dry eye market, it only makes sense that investors see tremendous value in the product launch.

These Gains Could Just Be The Beginning

All in all, NBY could be embarking on an adventure that drives the stock far further. With a minimal market cap and a product that many believe will come with tremendous sales, even after gains of more than 5X, the stock could still be trading at a compelling discount. It all depends on one word… Sales!

Investors will be watching closely to see how much revenue is driven by sales on Should the move help the company to capture any meaningful percentage of the dry eye market, the gains that we’ve seen over the past couple of sessions could prove to be the tip of the iceberg.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Do You Think?

Where do you think NBY is headed moving forward? Join the discussion in the comments below!

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.